
Gilead’s Bulevirtide Demonstrates Long-Term Sustained Virologic Response For Hepatitis D
At the ongoing European Association for the Study of the Liver (EASL) Congress 2025, Gilead announced findings on its hepatitis D (HDV) therapy, bulevirtide. Specifically, the therapy was studied as a standalone treatment and in combination with pegylated …